1. Introduction {#sec1}
===============

Many patients experience pain and discomfort after colonoscopy. An explanation for this observation is the retention of gas in the colon, as several liters of air are insufflated during colonoscopy. For decades, CO~2~ insufflation has been routinely used to create the pneumoperitoneum in lapraroscopic surgery. Conversely, room air insufflation has remained the standard of care in most endoscopy centres \[[@B1]\]. Preliminary studies indicate that insufflation of carbon dioxide (CO~2~) may reduce periprocedural pain. CO~2~ was first recommended 1953 to avoid gas combustion in the colon during electrocoagulation \[[@B2]\]. In 1986, the rapid absorption of CO~2~ in the colon and minimal interference with colonic circulation were described, therefore minimizing the risk of bowel ischemia \[[@B3]\]. CO~2~ is absorbed about 150 times faster compared to nitrogen and is rapidly eliminated through the lungs \[[@B4]\]. Interestingly, 30 minutes after insufflation with CO~2~, the gas has disappeared, whereas patients with standard room air insufflation still have a significant distension of both small bowel and colon \[[@B5]\]. Initial studies with a limited number of patients have suggested potential benefits for CO~2~ use: Sumanac et al. \[[@B6]\] examined 97 patients undergoing colonoscopy with either CO~2~ or room air insufflation and showed that 45% of the patients examined with room air had pain one hour after examination compared with only 9% in the CO~2~ insufflation group. Six hours after colonoscopy, the fraction of patients with pain was 31% in the room air group versus 7% in patients with CO~2~ insufflation. Conventional X-rays revealed colonic distension of more than 6 cm in diameter in 71% of patients assigned to room air compared with only 4% in the CO~2~ group \[[@B6]\]. Similarly, in the NORCCAP, a Norwegian colorectal prevention study \[[@B7]\], 267 patients underwent colonoscopy with insufflation of either room air or CO~2~, with the latter group experiencing less postprocedural pain. With recent new developments that facilitate the use of CO~2~, more data have become available supporting the observation that insufflation with CO~2~ causes less pain \[[@B8]--[@B10]\]. The same conclusion was drawn in the review of Dellon et al., which included 8 randomized controlled trials (RCTs) with two RCTs showing decreased flatus and 3 decreased bowel distension on abdominal radiography \[[@B11]\].

A large, population-based survey based on 7,370 colonoscopies performed in Norwegian endoscopy centers revealed that up to 24% of patients experience severe pain during colonoscopy \[[@B12]\]. According to one study, 20% of patients need more than two days before being able to return to their normal activities after screening colonoscopy \[[@B13]\]. These findings demonstrate that there exists a tremendous potential for improvement towards painless colonoscopy.

In addition to better periprocedural pain control, another potential benefit of CO~2~ use is that no gas aspiration is necessary during withdrawal due to the fast gas absorption. Better colonic insufflation may be associated with a better diagnostic yield and especially a higher polyp detection rate. Comfort during and after colonoscopy represents a major issue for patient tolerance and acceptance. It is imperative that the nowadays recommended longer withdrawal times, and consecutively longer insufflations, do not compromise patient comfort. It would be wrong to shorten the withdrawal time during colonoscopy to make concessions with respect to patient comfort.

The objective of the present randomized controlled double-blinded trial was to assess patient satisfaction, pain, and bloating between patients undergoing colonoscopy with CO~2~ insufflation versus standard room air.

2. Patients and Methods {#sec2}
=======================

In this randomized controlled trial, 219 consecutive patients undergoing colonoscopy in a private Swiss gastroenterology practice were enrolled between April 2008 to June 2008 (only one patient did not participate in this time period). Patients were randomly assigned to colonoscopy with either CO~2~ versus room air insufflation. This randomized trial was double blinded, as neither the patients nor the gastroenterologist were aware of the intervention. The randomisation was done with a dice for each patient. If the number was even, the patient underwent colonoscopy with CO~2~, if the number was uneven, colonoscopy with room air. The study nurse, without any involvement of the investigator, did the selection. The ethical committee approved the trial, and written patient consent was obtained for each patient for colonoscopy and for the study receiving patient study information including an informed consent section on a visit prior to the scheduled colonoscopy.

All patients that seemed medically fit for an ambulatory colonoscopy were enrolled in this study. No particular exclusion criteria were used to maximize the generalizability (external validity) of this study. All colonoscopies were done by the first author and carried out with standard Pentax endoscopes (EC-3885K and EC-380FKp) with a standard processor EPK 1000. For CO~2~ insufflation, the medical licensed and approved CO~2~-Efficent Insufflator device (EZEM company Westbury NY 11590, US) was used. This insufflator is connected to a 10 L CO~2~ bottle. The CO~2~ is then supplied over a tubing set connected with a branch connection to the water bottle tube directly connected to the endoscope. The flow rate (basal flow rate 0.5 L per minute increasing to 3 L per minute if necessary) can be controlled on demand over the standard air valve. Air supply with the Pentax processor or CO~2~ insufflation with the CO~2~ Efficent Insufflator cannot be acoustically discriminated. The valves for the endoscope using CO~2~ are identical with the standard valves. Moreover, the switch for the pump of the CO~2~ processor was hidden as was the switch for the insufflator. The front line of the processor and the CO~2~ insufflator were covered to mask the operational status. The setup was done by the assisting nurse prior to the start of the colonoscopy without knowledge of the examiner. Therefore, this was a truly double-blinded trial. All patients were sedated with propofol using standard procedures previously described \[[@B14]\]. A level of conscious sedation (now classified as moderate sedation) was targeted giving propofol boli of 10 or 20 mg according to ASA-Classification. The total dose of propofol was registered and used for later analysis.

The primary endpoint of the present investigation was overall pain scores. Secondary endpoints were bloating as well as overall satisfaction assessed on a 10-point visual analogue scale (VAS) before and after the examination at 1, 3, 6, and 24 hours.

The grading of the VAS were as follows: for pain: 0 = no pain at all, 10 = worst possible pain; for bloating: 0 = no bloating at all, 10 = terrible bloating; for satisfaction: 0 = not at all satisfied, 10 = perfectly satisfied.

As quality indicators and characteristics of the performed colonoscopy time to reach the ileum, withdrawal time, length of intervention, procedural length, and the number and the size (\>1 cm, \<1 cm, small polyp \<5 mm) of removed polyps and their histology were assessed. Finally, periprocedural complications were registered as well as time to discharge, propofol dosage, oxygen supply, and other medication given. We also continuously measured transcutaneous carbon dioxide with a Sentec Capnograph device (SenTec AG 4106 Therwil, Switzerland) for respiratory monitoring.

The patients were motivated at discharge to fill out the postprocedure survey regarding pain, bloating, and satisfaction. We purposefully and a priori decided not to call any patients who did not mail in the survey, as this would have potentially led to imprecise results from patients retrospectively filling out the survey.

2.1. Statistics {#sec2.1}
---------------

Statistical analyses were performed using SPSS Version 11.0, and the level of statistical significance was set at *P* \< .05. To compare dichotomous (yes/no) and categorical outcomes, the Chi Square test was used. For comparisons of continuous outcomes, unpaired *t*-tests were used.

The sample size computations were based on a difference for overall pain scores (the primary endpoint) with an effect size of 2 (overall pain score of 4 in the CO~2~ group versus 6 in the room air group). With a power of 80% (beta error of 20%), type I error of 5%, and standard deviation of 5, the resulting sample size was 200 patients.

3. Results {#sec3}
==========

A total number of 219 patients undergoing colonoscopy were enrolled in this study. One hundred and ten patients were randomized to the CO~2~ group and 109 to the room air group. The baseline characteristics of both groups are displayed in [Table 1](#tab1){ref-type="table"}. These baseline characteristics were similar in both groups with the exception of gender and the fraction of patients with irritable bowel syndrome: there were significantly more women (62% versus 47%, *P* = .03) and IBS patients in the CO~2~ group ([Table 1](#tab1){ref-type="table"}).

The duration to reach the ileum was 7.7 ± 4.7 minutes in the CO~2~ group and 6.7 ± 4.1 in the room air group (*P* \> .05). Withdrawal times were 13.6 ± 6.0 minutes in the CO~2~ group and 13.3 ± 6.1 minutes in the room air group (*P* \> .05). Outcomes are listed in [Table 2](#tab2){ref-type="table"}. In 10.9% of the patients in the CO~2~ group, relevant polyps were removed (relevant polyps were defined as by size over 1 cm, histology (e.g., villous and serrated) or by high grade dysplasia). In the air group, the corresponding percentage was 7.3%. Additional adenomas (smaller than 1 cm) were found in 34.5% versus 33.9%, respectively (*P* \> .05).

For the data collection in the office, data was complete for all patients. Seventy-five percent of group 1 and 82% of group 2 returned the completed questionnaire.

At all time points, the VAS scores for bloating and pain were lower in the CO~2~ group compared to the room air group (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}): patients experienced significantly less bloating at discharge, as well as one hour (*P* \< .001), three hours (*P* \< .001), and six hours after the procedure (*P* = .04). Also, patients randomized to CO~2~ experienced significantly less pain at one hour (*P* \< .001) and three hours (*P* \< .001) after the procedure. Overall pain summary scores for 24 hours were significantly lower in the CO~2~ group compared to the patients assigned to room air (3.6 ± 5.8 versus 6.1 ± 7.4, *P* = .014). Similarly, overall pain scores were significantly lower in patients randomized to CO~2~ versus room air (2.0 ± 3.8 versus 4.0 ± 5.0, *P* = .007). The percentage of patients, who did not experience any pain, was significantly higher in the group examined with CO~2~ up to 3 hours ([Table 3](#tab3){ref-type="table"}). Bloating was also significantly less in the above-mentioned time periods (*P* values between .023 to \<.001).

The overall acceptance of the colonoscopy was excellent in both groups. In the CO~2~ group, the overall satisfaction score was 9.6 ± 0.7 versus 9.3 ± 1.0 on a 10-point visual analogue scale.

CO~2~ was continuously measured. There was no significant difference with respect to transcutaneous CO~2~ levels between the CO~2~ and room air groups (pCO~2~ at the end of procedure in CO~2~ group: 35.7 ± 4.3 mmHg versus room air group: 35.8 ± 6.5 mmHg in group 2, [Figure 3](#fig3){ref-type="fig"}). In both groups, there was a slight increase in CO~2~ from baseline to the ileum; however, the CO~2~ values remained within normal range. In all patients, including the known COPD patients, the O~2~ saturation always stayed above 88% and no ventilation, manual, or mechanical airway assistance was required.

4. Discussion {#sec4}
=============

This represents the first large double-blinded randomized controlled trial comparing the use of CO~2~ versus room air in patients undergoing colonoscopy with propofol sedation using continuous monitoring by capnography for all patients. Our investigation provides compelling evidence that CO~2~ insufflation compared with standard room air significantly reduces bloating and pain in patients undergoing routine colonoscopy and stands in line with the review reported by Dellon et al. \[[@B11]\] and several other studies \[[@B9], [@B10], [@B15]\]. More important, the procedure is safe with no significant differences in CO~2~ measurements observed between the two groups. This is of utmost importance, since data are limited on this topic with safety still being debated in sedated patients.

The setting of the present investigation has several strengths. First, this study has a large sample size, notably not selected without any exclusion, neither for pulmonary disorders or former abdominal surgery. This makes it possible to transfer our data to a screening population without any restrictions (not even for COPD). Second, it is one of the few \[[@B10]\] studies comparing CO~2~ and room air use in a double-blinded randomized fashion. Third, all patients were sedated, and the CO~2~ group was continuously monitored. Fourth, only one endoscopist performed all procedures, which removes technical skills as a potential confounder. Fifth, the use of CO~2~ for routine colonoscopy was associated not only with significantly less pain and bloating but also with superior patient tolerance. This benefit is particularly remarkable considering that the CO~2~ group had significantly more women and more IBS patients compared to the room air group. Of note, CO~2~ benefits are observed immediately after the sedation. The pain reducing effect seems is most apparent and profound in the first 3 hours after the procedure, an observation that was also seen in other studies \[[@B10]\]. Thereafter, a tendency of lower pain perception persists. Stevenson et al. \[[@B16]\] showed a persisting benefit even at 24 hours. The duration of this benefit might vary depending on the amount of air inflated (which is endoscopist dependent), the examination time, and the interventions, making it most valuable for patients with large polyp resections.

Finally, the use of CO~2~ was not associated with a prolonged preparation time to set up or perform the procedure, and there were no side effects and no complications.

Abdominal pain after colonoscopy is common and distressing for some patients and can cause even sick leave \[[@B13]\]. It is due to bowel distension by the insufflating gas \[[@B12]\]. CO~2~ insufflation, as commonly used for establishing pneumoperitoneum during laparoscopic surgery, has already been proposed and introduced in different fields of endoscopy \[[@B17]--[@B19]\]. This procedure has a potential of resulting in less periprocedural pain, especially since new and easy to use insufflators are on the market. Increasingly sophisticated endoscopic procedures are currently being developed and performed. Some of them are time consuming such as endoscopic submucosal dissection (ESD) or therapeutic endoscopic retrograde cholangiopancreaticography (ERCP). Interestingly, an advantage for CO~2~ use was demonstrated in patients undergoing ERCP as well as ESD with respect to periprocedural pain \[[@B17], [@B18]\]. In a recently published trial by Domagk et al. \[[@B19]\], it was shown that CO~2~ use for balloon enteroscopy was not only less painful for patients, but also associated with a significantly deeper intubation length of the small intestine. Another advantage is that CO~2~ is less combustible in presence of stool or sub-optimal bowel preparation and, therefore, potentially safer when diathermy is being used. Moreover, it has advantages in longer procedures to avoid overdistention of the colon. However, the number of studies investigating the use of CO~2~ is limited and safety concerns with respect to respiratory side effects have been raised. This issue was assessed in three studies. The first including nonsedated patients undergoing colonoscopy showed a slight, however, clinically irrelevant (CO~2~ values within normal range) increase in end-tidal pCO~2~ with CO~2~ insufflation compared to room air use \[[@B20]\]. No difference in pCO~2~ was reported in the study of Yamano et al. \[[@B10]\] in nonsedated patients. In another small investigation, no difference was found between partially sedated patients undergoing colonoscopy with room air versus CO~2~. The authors concluded that CO~2~ insufflation was safe \[[@B21]\]. However, this investigation included only 29 sedated patients undergoing colonoscopy with the use of CO~2~. Here, we show the safety of CO~2~ insufflation in a large sample of sedated patients.

It is well known and intuitive that the success of any screening strategy is critically dependent on population acceptance of the screening methods; efforts to minimize discomfort associated with colonoscopy may positively influence compliance. With the prospect of widespread colonoscopy screening for colorectal cancer in asymptomatic populations, it is imperative to optimize patient comfort and convenience as well as the quality of the examination itself. Based on the findings of the present double-blinded, randomized controlled trial, CO~2~ appears to be important to reach this goal with less bloating, less pain, and higher patient satisfaction. The lack of awareness \[[@B1]\] of this compelling technique should be changed over time, as endoscopists are more and more convinced by growing evidence of the usefulness and safety of CO~2~ insufflation.

5. Strengths and Limitations {#sec5}
============================

We would like to acknowledge the limitations of this study. First, despite the randomized controlled study design, there were some imbalances between the CO~2~ and room air group with respect to gender and IBS. In fact, the CO~2~ group contained more female and IBS patients. However, it is well known that IBS and female patients usually have more pain and bloating after colonoscopy \[[@B22], [@B23]\]. Therefore, this will bias our findings towards the null hypothesis and the true benefit of CO~2~ colonoscopy may be even more important. Second, the randomization was done with a dice for each patient, and thus is theoretically prone to bias. However, a study nurse did the randomization without any involvement of the investigators, and therefore, the risk of bias is minimal.

There are several strengths of this study: first, this investigation was done in a double-blinded randomized, controlled fashion. Second, this is a large randomized patient sample; more important, there are only few reports that have investigated the benefit of CO~2~ in sedated patients with continuous CO~2~ monitoring. Third, there were no exclusion criteria in this study, and therefore, the generalizability (external validity) is high. Most importantly, the present trial addresses a very relevant and novel research questions and hopefully will help changing practice patterns.

6. Conclusion {#sec6}
=============

This study provides compelling evidence that CO~2~ insufflation is associated with significantly less bloating and pain during and after routine colonoscopy. Colonoscopy with CO~2~ insufflation is safe as no significant differences in CO~2~ measurements were observed. Based on these data, the routine use of CO~2~ insufflation for colonoscopy is encouraged.
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###### 

Baseline patient characteristics.

  -----------------------------------------------------------------------------------------
                             CO~2~ group *n* = 110   Room air group *n* = 109   *P* value
  -------------------------- ----------------------- -------------------------- -----------
  Age                        58 ± 13                 62 ± 12                    .42

  Sex                        Female:\                Female:\                   .03
                             62%                     47%                        

  BMI                        25 ± 4.7                26 ± 4.4                   .78

                                                                                

  Comorbidity                                                                   .36

   ASA I                     64.5%                   61.5%                      

   ASA II                    29.1%                   26.6%                      

   ASA III                   6.4%                    11.9%                      

   COPD                      2.7%                    2.8%                       .32

                                                                                

  Irritable bowel syndrome   23.6%                   12.8%                      .03

                                                                                

  Indication                                                                    .92

   Screening                 78.2%                   79.9%                      

   Surveillance              3.6%                    4.6%                       

   IBD                       6.4%                    4.6%                       
  -----------------------------------------------------------------------------------------

###### 

Parameters of colonoscopy in CO~2~ and room air group.

  --------------------------------------------------------------------------
                               CO~2~ group      Room air group   *P* value
  ---------------------------- ---------------- ---------------- -----------
  Propofol                     134 mg ± 56      120 mg ± 120     .9

  Nasal oxygen substitution\   10%              20.2%            .02
  if O~2~ saturation \<90%                                       

  Ileum intubation rate        95.5%^1^         97.2% ^1^        .22

  Time to ileum                7.7 ± 4.7 min    6.7 ± 4.1 min    .18

  Withdrawal time              13.6 ± 6.0 min   13.3 ± 6.1 min   .99

  Intervention time            3.3 ± 4.5 min    3.2 ± 4.6 min    .99

                                                                 

  Polyps                       68.2%            68.8%            .11

   \>1 cm                      8.2%             7.3%             

   0.5--1 cm                   17.3%            16.6%            

   \<0.5 cm                    63.6%            66.1%            

                                                                 

  Findings                                                       .77

   Carcinoma                   0.9%             1.8%             

   Relevant polyp^2^           10.9%            7.3%             

   Small adenoma^3^            34.5%            33.9%            

   Hyperplastic                13.6%            14.7%            

                                                                 

  CO~2~ (mmHg)                                                   

   at start                    33.4 ± 4.7       34.6 ± 5.1       .59

   at ileum                    37.3 ± 5.2       37.0 ± 5.2       .62

   end of examination          35.2 ± 4.3       35.6 ± 6.0       .01

  Maximal CO~2~ rise           4.2 ± 3.7        2.9 ± 4.4        .77
  --------------------------------------------------------------------------

^1^0.9% stenosis (e.g., tumor, or sigmoid stenosis due to diverticulosis) in both groups, reaching coecum in 99% in both groups.

^2^Relevant polyps defined as polyp \>1 cm, serrated, and villous ± high-grade dysplasia.

^3^Polyps size \<1 cm.

###### 

Pain sensation assessed by VAS Score.

  Time           Insufflation   \% (*n* = absolute numbers)   *P* value                           
  -------------- -------------- ----------------------------- ----------- ----------- ----------- ---------
  End            CO~2~          59 (65)                       24.5 (27)   14.5 (16)   2 (2)       .94
                 Air            57.7 (63)                     23 (25)     16.5 (18)   2.8 (3)     
                                                                                                  
  Discharge      CO~2~          73.6 (81)                     14.5 (16)   10.9 (12)   0.1 (1)     .23
  (15--30 min)   Air            64.2 (70)                     22 (24)     8.3 (9)     5.5 (6)     
                                                                                                  
  1 h            CO~2~          68.8 (55)                     22.5 (18)   8.8 (7)     0           \<.0001
                 Air            36.4 (32)                     34 (30)     18.2 (16)   11.4 (10)   
                                                                                                  
  3 h            CO~2~          72.2 (57)                     21.5 (17)   6.3 (5)     0           .015
                 Air            51.1 (45)                     28.4 (25)   14.8 (13)   5.7 (5)     
                                                                                                  
  6 h            CO~2~          73.8 (59)                     20 (16)     6.2 (5)     0           .53
                 Air            66 (58)                       22.7 (20)   10.2 (9)    1.1 (1)     
                                                                                                  
  24 h           CO~2~          87.5 (70)                     7.5 (6)     5 (4)       0           .67
                 Air            86.4 (76)                     11.4 (10)   2.3 (2)     0           
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